You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Dexcom reported third-quarter revenue of $1.34 billion, up 11%, raised 2026 revenue guidance to $5.20 to $5.25 billion, and increased operating profit margin guidance to approximately 24% and adjusted EBITDA margin guidance to approximately 32%.
Dexcom's third-quarter 2026 revenue rose 11% to $1.34 billion and gross profit rose 18% to $864.4 million, but operating cash flow fell 51% to $325.6 million and net income fell 3% to $275.1 million.
Dexcom reported third-quarter revenue growth of 11% to $1.344 billion and raised fiscal year 2026 revenue guidance to $5.20 - $5.25 billion. Its board authorized up to $1.0 billion in share repurchases ending no later than December 31, 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Dexcom reported 11% revenue growth, expanded gross and operating margins, raised fiscal 2026 revenue and operating-margin guidance, and generated over $900 million of free cash flow while authorizing another $1 billion in share repurchases. CONNECT publication, G7 15-day adoption, and planned international launches support future growth, while GAAP net income declined year over year and updated guidance includes approximately $5 million of incremental foreign-exchange headwinds.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 785.8M | Six Months Ended June 30, 2026 | — |
| Non-GAAP diluted net income per share non-GAAP | $1.26 | Six Months Ended June 30, 2026 | — |
| Non-GAAP diluted weighted-average shares outstanding non-GAAP | 384.1M | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | 1.6B | Six Months Ended June 30, 2026 | — |
| Non-GAAP net income non-GAAP | 485.4M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating income non-GAAP | 592.7M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DXCM
this stock
Dexcom Inc
|
$31.08B | +25.6% | +60.2% | 32.8 | 4.3% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Dexcom's third-quarter 2026 revenue rose 11% to $1.34 billion and gross profit rose 18% to $864.4 million, but operating cash flow fell 51% to $325.6 million and net income fell 3% to $275.1 million.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DXCM | +4.9% | -3.2% | +15.7% | +1.3% | +25.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.4% | -2.0% | +15.2% | +1.4% | +14.9% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
